🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Zoom, Kodak and Tesla Rise Premarket

Published 09/01/2020, 08:01 AM
Updated 09/01/2020, 08:02 AM
F
-
MCD
-
AAPL
-
WMT
-
TSLA
-
AZN
-
KODK
-
ZM
-

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Tuesday, September 1st. Please refresh for updates.

  • Zoom Video Communications (NASDAQ:ZM) stock rose 30% after the popular videoconferencing app saw its revenues soar with its second quarter profits more than doubling as the coronavirus crisis caused many people to work from home.

  • Eastman Kodak (NYSE:KODK) stock jumped 43% after hedge fund D.E Shaw disclosed a 5.2% stake in the company. This stock has been highly volatile in recent weeks after initially being granted a federal loan to produce drug ingredients, before the loan was put on hold.

  • Tesla (NASDAQ:TSLA) stock climbed 2.4%, despite plans to raise up to $5 billion through a share offering, continuing the recent positive momentum after the electric car manufacturer announced a 5-for-1 stock split, which took effect on Monday.  

  • Apple (NASDAQ:AAPL) stock climbed 2.3% after Bloomberg reported that the company is preparing to make 75 million iPhones in its big round of launches in October.

  • Walmart (NYSE:WMT) stock rose 2.8% after the retail giant unveiled the perks of its new membership program, Walmart Plus, to be launched on Sept. 15. These include unlimited free delivery, fuel discounts and no checkout lines.

  • McDonald’s (NYSE:MCD) stock fell 0.4% after 52 black former franchise owners launched a lawsuit, seeking up to $1 billion of damages after accusing the fast-food giant of racial discrimination. 

  • Ford (NYSE:F) stock fell 0.2% after announcing plans to cut about 1,000 jobs in North America as part of an $11 billion global restructuring begun two years ago as it projects an operating loss this year.

  • AstraZeneca (NYSE:AZN) ADR rose 0.1% after the U.K.-based pharmaceutical said it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile Covid-19 vaccine candidate.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.